PLEASANTON, Calif., Apr 19, 2012 (BUSINESS WIRE) –
ZELTIQ Aesthetics, Inc.
, a medical technology company
focused on developing and commercializing products utilizing its
proprietary controlled-cooling technology platform, announced that
criminal judgments and monetary fines have been ordered by Seoul Central
District Court in South Korea against two individuals for false and
exaggerated advertising of a cooling device that has not been approved
for fat reduction. ZELTIQ is the only company that has received approval
from the Korea Food and Drug Administration (KFDA) to market and sell a
device that achieves fat reduction through controlled cooling.
Criminal proceedings in South Korea were instituted against two
individuals who were using Internet pages and blogs to falsely advertise
that other cooling devices had the same fat reducing effect as ZELTIQ’s
approved device. After a police investigation into these advertising
activities, criminal proceedings were initiated. Seoul Central District
Court has now imposed monetary fines and finalized criminal judgments on
the counts of false and exaggerated advertising. The Korean police are
also currently investigating additional advertising activities and acts
of trademark infringement.
Steve Atkinson, SVP of International at ZELTIQ, commented, “ZELTIQ has
invested substantial efforts to develop safe and effective devices that
are approved for fat reduction and has secured regulatory approvals for
those devices. ZELTIQ will vigilantly pursue persons or companies that
are attempting to confuse or mislead consumers or physician-providers by
inferring that any cold platform technology can do what the
CoolSculpting System uniquely has proven we can safely do: reduce
exercise-resistant fat non-surgically. We will not stand idly by while
poseurs try to muddy our clear advantages.”
Atkinson added, “We firmly believe that the recent criminal judgments in
South Korea will deter others from marketing and selling products that
do not use proven technology or have the same regulatory approvals as
For more information on ZELTIQ, visit
About ZELTIQ(R) Aesthetics, Inc.
ZELTIQ Aesthetics is a medical technology company focused on developing
and commercializing products utilizing its proprietary
controlled-cooling technology platform. The Company’s first commercial
product, the CoolSculpting(R) System, is designed to selectively reduce
stubborn fat bulges that may not respond to diet or exercise.
CoolSculpting is based on the scientific principle that fat cells are
more sensitive to cold than the overlying skin and surrounding tissues.
CoolSculpting utilizes patented technology of precisely controlled
cooling to reduce the temperature of fat cells in the treated area,
which is intended to cause fat cell elimination through a natural
biological process known as apoptosis, without causing scar tissue or
damage to the skin, nerves, or surrounding tissues. ZELTIQ developed
CoolSculpting to safely, noticeably, and measurably reduce the fat layer
within a treated fat bulge without requiring the patient to diet or
SOURCE: ZELTIQ Aesthetics, Inc.
MEDIA CONTACT: ZELTIQ Steve Atkinson, International SVP +44 (0)1293 897452 or GOLD PR for ZELTIQ Shari Gold 714-251-0375 or INVESTOR RELATIONS: ZELTIQ Josh Brumm, CFO 925-474-2500 or The Ruth Group for ZELTIQ Nick Laudico / Amy Glynn 646-536-7030 / 7023
Copyright Business Wire 2012
Add to portfolio